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Abstract Extracellular superoxide dismutase (EC-SOD) is a
secretory protein that is the major SOD isozyme in extracellular
fluids. Plasma EC-SOD levels are distributed in two discrete
groups with the rare group having an enzyme with glycine instead
of arginine-213, which causes a 10-fold higher serum level.
Within the common phenotype group, the urinary EC-SOD level
was significantly correlated with the urinary excretion of N-
acetyl-L-D-glucosaminidase (NAG), but not with serum EC-
SOD. EC-SOD appears not to be leaked from the plasma by
glomerular filtration, but rather to be secreted from the renal
tubule or its surrounding tissues. The urinary EC-SOD level was
also significantly correlated with the urinary cyclic adenosine
monophosphate (cAMP) level. cAMP analogues and adenylate
cyclase modulators significantly stimulated the expression of
EC-SOD but not other SOD isozymes in cultured fibroblast cell
lines. Moreover, injection of parathyroid hormone, in Ellsworth-
Howard tests, increased urinary EC-SOD accompanied with the
elevations of urinary cAMP and NAG. Together these observa-
tions suggest that factor(s) that stimulate the adenylate cyclase-
cAMP system regulate the urinary EC-SOD level.
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Superoxide and other secondarily generated active oxygen
metabolites are continuously generated as normal by-products
of cellular metabolism. These oxygen metabolites are highly
reactive and can attack many biochemical components in the
cells. Normal cells have a number of enzymatic endogenous
antioxidant mechanisms, such as superoxide dismutase (SOD,
EC. 1.15.1.1), catalase and glutathione peroxidase. These en-
zymes quickly eliminate toxic oxygen metabolites under phys-
iological conditions. When the £ux of active oxygen metabo-
lites exceeds the capability of endogenous antioxidant
mechanisms, tissue injury ensues, because the generation of
highly toxic metabolites of oxygen is greatly increased under
pathological conditions [1].
There are three SOD isoforms, copper- and zinc-containing
SOD (Cu,Zn-SOD), manganese-containing SOD (Mn-SOD)
and extracellular-SOD (EC-SOD). Cu,Zn-SOD and Mn-
SOD are intracellular SOD isozymes with molecular weights
of 32 kDa and 85 kDa and are found predominantly in the
cytoplasm and mitochondria, respectively. EC-SOD, the most
recently discovered SOD isozyme, is a secretory, copper- and
zinc-containing glycoprotein with an apparent molecular
weight of 135 kDa [2,3]. Blood vessel walls contain large
amounts of EC-SOD and this enzyme is the principal enzy-
matic scavenger of superoxide in the vascular system, whereas
EC-SOD is the least abundant enzyme in other tissues [4,5]. A
prominent feature of EC-SOD is its a⁄nity to heparin-like
substances [2,6] and more than 99% of this enzyme is an-
chored to heparan sulfate proteoglycans in the interstitium
of tissues, especially blood vessel walls [4]. The less than 1%
of EC-SOD is present in the circulation in equilibrium be-
tween the plasma phase and the glycocalyx of the endothelium
[4,7]. Molecular genetic studies of EC-SOD have shown that
a single base substitution causing exchange of glycine for ar-
ginine-213 (R213G) in the heparin-binding domain of this
enzyme causes an extremely high plasma level of EC-SOD
[8^10]. The high plasma EC-SOD phenotype is found in about
2 to 6% of healthy subjects in Japanese, Swedish and Austra-
lian populations [8,10^14]. We have reported that the plasma
levels of the common phenotype EC-SOD and the frequency
of the R213G mutation were higher in hemodialysis patients
than in healthy persons [10,15]. On the other hand, little is
known about urinary EC-SOD. We reported that urinary EC-
SOD levels in patients with renal diseases were, in contrast to
the serum levels, lower than those in healthy subjects [15].
However, it is still unclear how urinary EC-SOD changes.
In the present study, our ¢ndings suggest that the urinary
EC-SOD level is regulated by cyclic adenosine monophos-
phate (cAMP)-mediated renal tubule function.
2. Materials and methods
2.1. Subjects
The subjects studied were healthy individuals who had participated
in an annual health checkup. They were free of any abnormality on
physical examination, blood chemical screening, electrocardiogram,
chest X-ray and urinalysis. Blood samples were taken without anti-
coagulant. The blood samples were centrifuged within 2 h and sera
were stored at 370‡C in aliquots until analysis. The urinary samples
were ¢rst morning urine.
2.2. Assay
The EC-SOD concentration was determined by an enzyme-linked
immunosorbent assay (ELISA) as described previously [11]. Cu,Zn-
SOD and Mn-SOD were determined using ELISA kits purchased
from NOF (Tokyo, Japan). The other assays were performed by the
standard clinical examination methods. Data obtained by urinalysis
were normalized by the urinary creatinine (CRE) concentration.
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2.3. Fibroblast cell culture
Human skin ¢broblast cell lines were initiated from skin punch
biopsy specimens obtained from four volunteers, using Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS), 4 mM glutamine, 100 units/ml penicillin and 100
Wg/ml streptomycin as medium. They were kept in 5% CO2/95% air at
37‡C. Cells (2U105 cells/well) were plated in six-well plates and cul-
tured for 3 days; then the medium was changed to FCS-free culture
medium and the cells were cultured for another 24 h. The cells were
then cultured for 4 days in FCS-free culture medium with or without
reagents such as adenosine triphosphate (ATP, Oriental Yeast, Tokyo,
Japan), N6-2P-O-dibutyryl cAMP (dbcAMP, Nacalai Tesque, Kyoto,
Japan), 8-bromo cAMP (8BrcAMP, Sigma St. Louis, MO), forskolin
(Wako Pure Chemical Industries, Osaka, Japan) and 3-isobutyl-1-
methylxanthine (IBMX, Wako Pure Chemical Industries). The me-
dium was then removed for the assay of EC-SOD, and the cells
were washed twice with 2 ml of cold phosphate bu¡ered saline
(PBS). The cells were then detached by sonication and collected into
0.5 ml of PBS. Cell protein was assayed by the Bradford method [16].
2.4. Ellsworth-Howard test
The Ellsworth-Howard test was done in four healthy laboratory
personnel members according to the standard protocol of the Ministry
of Health and Welfare investigation research group in Japan. Before
and after the intravenous injection of 100 U of teriparatide acetate,
Human parathyroid hormone (PTH) (Asahi Kasei, Tokyo, Japan),
urine was collected every hour.
2.5. Statistical analyses
Data are presented as means þ S.D., and changes within groups
were analyzed by paired two-tailed Student’s t-test.
3. Results and discussion
3.1. Urinary EC-SOD level
Normal individuals are divided into two groups; one with
common phenotype EC-SOD and one with the rare pheno-
type EC-SOD with R213G exchanged enzyme. We measured
serum and urinary EC-SOD levels of 10 subjects (male n = 3,
female n = 7, age range 20 to 59) with the rare phenotype of
EC-SOD and 77 subjects (male n = 20, female n = 57, age
range 21 to 71) with the common EC-SOD phenotype in
the current study. Similar to our previous ¢ndings [11], the
rare phenotype group showed signi¢cantly (10-fold) higher
serum EC-SOD levels than the common phenotype group
(741 þ 145 Wg/l vs 74.6 þ 22.1 Wg/l, P6 0.0001). The EC-SOD
levels of these two groups were distributed in completely dis-
crete ranges of 580 to 1023 Wg/l and 37.7 to 145 Wg/l, respec-
tively. We found that the urinary level of the EC-SOD of the
rare phenotype group (24.8 þ 10.9 Wg/g CRE) was also signi¢-
cantly higher than that of the common phenotype group
(14.5 þ 5.6 Wg/g CRE, P = 0.015); however, their distribution
ranges overlapped. It is known that the R213G variation in
EC-SOD decreases the a⁄nity to heparin-like glycosaminogly-
cans on the endothelial cell surface, and this causes the high
plasma level of this enzyme [8,17]. It is possible that such EC-
SOD with low heparin-a⁄nity is highly distributed into the
urine due to ine⁄cient trapping within the interstitium be-
tween the expressing cells and the urinary space.
3.2. Correlations between urinary EC-SOD and other chemical
values
The aim of the current study was to identify the factor(s)
regulating the urinary EC-SOD level in common phenotype
subjects. Within the common phenotype group, there was no
signi¢cant correlation between urinary EC-SOD and serum
EC-SOD levels (r = 0.124, P = 0.281). It is known that
Cu,Zn-SOD in plasma is excreted rapidly by glomerular ¢l-
tration [18,19] Compared to Cu,Zn-SOD, with molecular
weight of 32 kDa, EC-SOD is larger (135 kDa) and would
not pass through the capillary basement of the glomerular
¢ltration apparatus of the kidney. Moreover, the high a⁄nity
to the endothelial cell surface decreases the rate of loss of EC-
SOD from the circulation [20]. Karlsson and Marklund re-
ported that human EC-SOD intravenously injected into rab-
bits was distributed mainly to the liver and slightly to the
kidney and spleen and other organs [21]. Although the major
site of EC-SOD degradation was not deduced, the liver is
likely candidate for this [21]. Under physiological conditions,
proteins found in the urine are classi¢ed into two groups:
plasma proteins leaked from the glomerulus by ¢ltration,
such as albumin, and proteins derived from the renal tubule,
such as N-acetyl-L-D-glucosaminidase (NAG). In healthy in-
dividuals studied here, the urinary total protein concentration
was signi¢cantly correlated with urinary NAG (r = 0.342,
P = 0.0023). It has been reported that some exogenous factors
transiently increased the urinary excretion of NAG without
any renal tubular damage [22], however an increase of urinary
NAG is generally inferred to represent a leakage of the en-
zyme from the damaged renal tubular cells. Urinary EC-SOD
was signi¢cantly correlated with NAG (r = 0.289, P = 0.0107),
but not with urinary total protein (r = 0.101, P = 0.381) (Fig.
1). We found that Green Monkey kidney ¢broblasts expressed
EC-SOD, while human cultured renal tubule epidermal cells
did not (data not shown). Together, these ¢ndings suggest
that EC-SOD in urine might be not leaked from the plasma,
but may rather be secreted from ¢broblasts in the renal tubule
or its surrounding tissues.
Fig. 1. Correlation between EC-SOD and other substances in urine.
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In humans, EC-SOD is reported to be expressed by ¢bro-
blasts, glial cells, smooth muscle cells and lipid-laden macro-
phages [23^26]. The synthesis of EC-SOD by ¢broblasts is
regulated by some in£ammatory cytokines [27] and not by
oxidative stress [28]. Nicola|« et al. reported that EC-SOD
transcription and secretion were enhanced by cAMP in a rat
glioma cell line [29]. cAMP is known to be an intracellular
second messenger that regulates the expression of proteins
including nitric oxide synthase [30] and many other proteins.
A cAMP-producing enzyme, adenylate cyclase, is a compo-
nent of the cAMP-dependent signaling pathway in renal tu-
bules and is activated by many substances, such as PTH,
glucagon, catecholamine and prostaglandins. The renal excre-
tion of phosphate (Pi) is also stimulated by PTH through this
pathway. Since part of the cAMP synthesized in tubules leaks
into the urine and can be detected there, the assay of urinary
cAMP concentration is used as a diagnostic test of the hor-
monal function of PTH. In samples tested in the current
study, urinary Pi was signi¢cantly correlated with urinary
cAMP (r = 0.526, P = 0.0006). In agreement with a previous
report [22], urinary NAG was also correlated with urinary
cAMP (r = 0.507, P6 0.0001), while urinary protein was not
(r = 0.150, P = 0.1925). We found that urinary EC-SOD was
signi¢cantly correlated with urinary cAMP (r = 0.454,
P6 0.0001) and urinary Pi (r = 0.405, P = 0.0106) (Fig. 1).
These results suggest that the factor(s) that elevate the cellular
cAMP level enhance the expression of EC-SOD in the renal
tubule tissue and enhance the urinary excretion of this en-
zyme. To extend the above observations, we carried out in
vitro experiments on the e¡ect of cAMP on the expression
of EC-SOD in cultured cell lines, and performed an in vivo
experiment with volunteers to test the e¡ect of PTH injection
on the urinary excretion of EC-SOD.
3.3. E¡ect of cAMP on EC-SOD expression by ¢broblasts
We investigated the e¡ect of elevation of the cellular cAMP
level on the expression of EC-SOD in ¢broblasts. Extracellu-
lar ATP and cAMP analogues such as dbcAMP and
8BrcAMP have been reported to elevate the intracellular
cAMP level in several di¡erent cell types [29^31]. We con-
¢rmed the elevation of cAMP by the addition of above re-
agents. (data not shown). As shown in Fig. 2, the level of EC-
SOD expression varied a lot among the cell lines. However,
the responses for reagents were in a similar manner. The ad-
dition of ATP, dbcAMP and 8BrcAMP to the medium sig-
ni¢cantly increased the expression of EC-SOD, 4.63-fold,
2.03-fold and 3.13-fold, respectively. The stimulation of EC-
SOD synthesis is not due to stimulation of cell growth, since
the protein content in the cell layer did not increase. On the
other hand, these reagents did not induce the signi¢cant
changes in the levels of Cu,Zn-SOD and Mn-SOD. The nu-
cleotide sequence of the human EC-SOD gene has been re-
ported, and a cAMP-responsive element was found at position
3438 bp [32]. In fact, it was reported that EC-SOD mRNA
transcription was enhanced dose-dependently by cAMP ana-
logues [29]. We next tested the e¡ect of modulators of adenyl-
ate cyclase-cAMP system on the EC-SOD expression. The
adenylate cyclase activator forskolin and the phosphodiester-
Fig. 3. E¡ect of forskolin and IBMX on the expression of SODs by
¢broblast cells. Fibroblast cells (b,a,R,O) obtained from four vol-
unteers were cultured for 4 days in the absence or presence forsko-
lin (10 WM and 100 WM) and IBMX (100 WM and 1 mM) by the
methods described in Section 2. Each cross is the mean þ S.D. of
the four ¢broblast cell lines. *: P6 0.05; **: P6 0.01 compared to
control.
Fig. 2. E¡ect of ATP, dbcAMP and 8BrcAMP on the expression of SODs by ¢broblast cells. Fibroblast cells (b,a,R,O) obtained from four
volunteers were cultured for 4 days in the absence or presence of ATP (500 WM), dbcAMP (500 WM) and 8BrcAMP (500 WM) by the methods
described in Section 2. SODs were assayed by the methods described in Section 2. Each cross is the mean þ S.D. of the four ¢broblast cell lines.
*: P6 0.05 compared to control.
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ase inhibitor IBMX signi¢cantly induced the expression of
EC-SOD by ¢broblasts, as shown in Fig. 3. These results
imply that EC-SOD expression would be constantly regulated
by several factors through the cAMP-dependent signaling sys-
tem.
3.4. E¡ect of cAMP elevation on urinary EC-SOD level in vivo
The Ellsworth-Howard test is a PTH load test which mon-
itors the PTH hormonal function mediated through the PTH-
receptor on renal tubules. After the injection of PTH accord-
ing to the protocol of the Ellsworth-Howard test, PTH,
cAMP, NAG and Pi in the urine were signi¢cantly elevated
(Fig. 4), whereas urinary protein and CRE were only slightly
changed (data not shown). A positive correlation between the
increase of urinary NAG and the increase of cAMP excretion
after PTH injection has been reported [22]. Moreover, a
cAMP-dependent mechanism has been suggested to contrib-
ute to the urinary NAG excretion [22]. The EC-SOD in urine
was also signi¢cantly increased after the injection of PTH
(Fig. 4). The results of the Ellsworth-Howard test thus suggest
that the urinary excretion of EC-SOD might be due to the
stimulation of the adenylate cyclase-cAMP system and were in
agreement with the population study described above.
We have reported that the plasma level of common pheno-
type EC-SOD was higher in patients with renal diseases, while
urinary EC-SOD levels in patients were lower than those in
healthy subjects [15]. In this study, we found that urinary
common phenotype EC-SOD correlated with urinary cAMP
and Pi, but not with serum EC-SOD and urinary protein. We
therefore tested whether cAMP contributes to the regulation
of EC-SOD expression by in vitro experiments with ¢broblast
cell lines and in vivo experiment to test the e¡ect of PTH
injection to healthy laboratory personnel members. The ele-
vation of cAMP in ¢broblast cell lines by the addition of the
substrate of adenylate cyclase, cAMP analogues, adenylate
cyclase activator, and phosphodiesterase inhibitor increased
the expression of EC-SOD especially but not other SODs.
In Ellsworth-Howard test, injection of PTH induced the ele-
vation of urinary EC-SOD accompanied with the elevation of
cAMP, NAG and Pi in the urine. Taken together, our data
suggest that urinary EC-SOD does not come from the plasma
EC-SOD. Whilst the mechanism remains speculative, it is pos-
sible that expression of EC-SOD by the ¢broblasts in or sur-
rounding the renal tubule is enhanced by the elevation of
cellular cAMP and this leads to the increase of the urinary
EC-SOD level.
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